BioNTech SE (NASDAQ:BNTX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of BioNTech SE (NASDAQ:BNTX) have earned an average rating of “Moderate Buy” from the seventeen ratings firms that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $142.72.

BNTX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. decreased their price target on BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 26th. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and raised their target price for the company from $90.00 to $137.00 in a research note on Friday, November 8th. TD Cowen reduced their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research report on Tuesday, November 5th. Finally, BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a research report on Monday, December 2nd.

Hedge Funds Weigh In On BioNTech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Planning Capital Management Corp raised its position in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares during the period. Blue Trust Inc. increased its stake in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares in the last quarter. GAMMA Investing LLC raised its holdings in BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after purchasing an additional 111 shares during the period. Daiwa Securities Group Inc. boosted its position in shares of BioNTech by 430.3% during the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after purchasing an additional 1,562 shares in the last quarter. Finally, Clear Harbor Asset Management LLC acquired a new position in shares of BioNTech in the 3rd quarter valued at $210,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Stock Down 0.7 %

Shares of NASDAQ BNTX opened at $111.93 on Thursday. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The business has a fifty day moving average of $114.75 and a two-hundred day moving average of $104.99. The stock has a market cap of $26.83 billion, a PE ratio of -53.30 and a beta of 0.18.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $2.07. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s quarterly revenue was up 38.9% on a year-over-year basis. During the same period last year, the firm posted $0.73 EPS. As a group, equities research analysts expect that BioNTech will post -3.71 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.